Annual report
7446.TEDINET S100SHTA
Period2022-10-01 → 2023-09-30
Filed2023-12-21
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥36.2bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.0bn | 2019-10-01 → 2020-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.0bn | 2018-10-01 → 2019-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥751m | 2022-10-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥944m | 2021-10-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥759m | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥410m | 2019-10-01 → 2020-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥330m | 2018-10-01 → 2019-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥805m | 2022-10-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥975m | 2021-10-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥517m | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥378m | 2019-10-01 → 2020-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥221m | 2018-10-01 → 2019-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥567m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥681m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥17.5bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥16.1bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.6bn | at 2020-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.8bn | at 2019-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2021-09-30d | Cons. | Net assets |
| Net assets / equity | ¥5.7bn | at 2020-09-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.4bn | at 2019-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥660m | at 2021-09-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥730m | at 2020-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥596m | at 2019-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.3bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥886m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥322m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥441m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥765m | 2018-10-01 → 2019-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥335m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥92m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥172m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥205m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥143m | 2018-10-01 → 2019-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥96m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥186m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥221m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥511m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥15m | 2018-10-01 → 2019-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥564.91 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥404.57 | 2019-10-01 → 2020-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.3 | 2018-10-01 → 2019-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥7,971.19 | at 2023-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥7,330.63 | at 2022-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥6,829.86 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥6,023.38 | at 2020-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,693.08 | at 2019-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.5% | at 2020-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2019-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.1% | 2022-10-01 → 2023-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-10-01 → 2022-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-10-01 → 2020-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2018-10-01 → 2019-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 321 | at 2023-09-30 | Cons. | Number of employees |
| Employees | 321 | at 2022-09-30 | Cons. | Number of employees |
| Employees | 316 | at 2021-09-30d | Cons. | Number of employees |
| Employees | 314 | at 2020-09-30d | Cons. | Number of employees |
| Employees | 309 | at 2019-09-30d | Cons. | Number of employees |
| Revenue | ¥27.4bn | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥28.4bn | 2021-10-01 → 2022-09-30 | Standalone | Net sales |
| Revenue | ¥27.8bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.4bn | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.3bn | 2018-10-01 → 2019-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥687m | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Operating income | ¥792m | 2021-10-01 → 2022-09-30 | Standalone | Operating income |
| Ordinary income | ¥739m | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥846m | 2021-10-01 → 2022-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥633m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥380m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥318m | 2018-10-01 → 2019-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥719m | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥817m | 2021-10-01 → 2022-09-30 | Standalone | Income before income taxes |
| Net income | ¥495m | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | ¥547m | 2021-10-01 → 2022-09-30 | Standalone | Profit loss |
| Net income | ¥424m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥356m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥214m | 2018-10-01 → 2019-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥15.2bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥14.1bn | at 2022-09-30 | Standalone | Assets |
| Total assets | ¥13.0bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.7bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.7bn | at 2019-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥8.4bn | at 2023-09-30 | Standalone | Liabilities |
| Total liabilities | ¥7.8bn | at 2022-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥6.8bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2022-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2021-09-30d | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥5.3bn | at 2019-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2023-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2022-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥549.54 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥606.07 | 2021-10-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥463.89 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥380.41 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥228.09 | 2018-10-01 → 2019-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥105 | 2022-10-01 → 2023-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥115 | 2021-10-01 → 2022-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2020-10-01 → 2021-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2019-10-01 → 2020-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2018-10-01 → 2019-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥7,552.81 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,987.67 | at 2022-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,615.32 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥5,917.64 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥5,610.97 | at 2019-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 44.8% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.7% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.4% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.4% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.9% | at 2019-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.6% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-10-01 → 2022-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.1% | 2018-10-01 → 2019-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 960,000 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2019-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 244 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 236 | at 2022-09-30 | Standalone | Number of employees |
| Employees | 230 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 228 | at 2020-09-30d | Standalone | Number of employees |
| Employees | 226 | at 2019-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | employees | at 2023-09-30 | 6 pure |
| Otherother segments | revenue | 2022-10-01 → 2023-09-30 | ¥370m |
| Otherother segments | revenue external | 2022-10-01 → 2023-09-30 | ¥370m |
| Foodreportable segment | employees | at 2023-09-30 | 15 pure |
| Foodreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥3.3bn |
| Foodreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥3.3bn |
| Pharmaceutical Productsreportable segment | employees | at 2023-09-30 | 74 pure |
| Pharmaceutical Productsreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥17.2bn |
| Pharmaceutical Productsreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥17.2bn |
| Reagent For Clinical Testreportable segment | employees | at 2023-09-30 | 73 pure |
| Reagent For Clinical Testreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥14.2bn |
| Reagent For Clinical Testreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2023-09-30 | ¥35.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2023-09-30 | ¥35.1bn |
| Otherother segments | revenue | 2021-10-01 → 2022-09-30 | ¥384m |
| Otherother segments | revenue external | 2021-10-01 → 2022-09-30 | ¥384m |
| Foodreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥3.3bn |
| Foodreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥3.3bn |
| Pharmaceutical Productsreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥18.0bn |
| Pharmaceutical Productsreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥18.0bn |
| Reagent For Clinical Testreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥15.6bn |
| Reagent For Clinical Testreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-09-30 | ¥37.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-09-30 | ¥37.3bn |
| Otherother segments | employees | at 2023-09-30 | 2 pure |
| Foodreportable segment | employees | at 2023-09-30 | 6 pure |
| Pharmaceutical Productsreportable segment | employees | at 2023-09-30 | 69 pure |
| Reagent For Clinical Testreportable segment | employees | at 2023-09-30 | 33 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,603
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)日本電子㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)㈱堀場製作所 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)エスペック㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)セントラル硝子㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)ＤＯＷＡホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)東ソー㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)多木化学㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)売却を検討しております | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)㈱プロクレアホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)金融機関との取引を維持・強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | ＡＧＣ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)三菱マテリアル㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)売却を検討しております | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)㈱レナサイエンス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row15Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)応用地質㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row16Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)ニプロ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row17Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)㈱寺岡製作所 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)売却を検討しております | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)㈱アルバック | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)主として化学工業薬品セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)Ｈ.Ｕ.グループホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)主として臨床検査試薬セグメントでの取引先関係の維持・強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)㈱カイノス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)主として臨床検査試薬セグメントでの取引先関係の維持・強化のため |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |